CR20220644A - Derivados de sulfona - Google Patents

Derivados de sulfona

Info

Publication number
CR20220644A
CR20220644A CR20220644A CR20220644A CR20220644A CR 20220644 A CR20220644 A CR 20220644A CR 20220644 A CR20220644 A CR 20220644A CR 20220644 A CR20220644 A CR 20220644A CR 20220644 A CR20220644 A CR 20220644A
Authority
CR
Costa Rica
Prior art keywords
sup
sulfone derivatives
formula
present
compounds
Prior art date
Application number
CR20220644A
Other languages
English (en)
Inventor
Andrew Simon Bell
Hoorn Willem Paul Van
Andreas Kuglstatter
Jérémy BESNARD
Anthony Richard Bradley
Luke Green
Claus Riemer
Buelent Kocer
Wolfgang Haap
Patrizio Mattei
Xavier Lucas
Dmitry Mazunin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220644A publication Critical patent/CR20220644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula I en donde X1 , X2 , X3 , X4 , R1 , R1a, R1b, R2’, R2”, R3’, R3”, R6 y R7 son como se describe en la presente descripción, así como también sus sales aceptables desde el punto de vista farmacéutico. Además, la presente invención se refiere a la fabricación de compuestos de Fórmula I, composiciones farmacéuticas que los comprenden y su uso como medicamentos.
CR20220644A 2020-06-22 2021-06-21 Derivados de sulfona CR20220644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181363 2020-06-22
PCT/EP2021/066767 WO2021259831A1 (en) 2020-06-22 2021-06-21 Sulfone derivatives

Publications (1)

Publication Number Publication Date
CR20220644A true CR20220644A (es) 2023-02-17

Family

ID=71120071

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220644A CR20220644A (es) 2020-06-22 2021-06-21 Derivados de sulfona

Country Status (19)

Country Link
US (1) US12565497B2 (es)
EP (1) EP4168392A1 (es)
JP (1) JP7731381B2 (es)
KR (1) KR20230026479A (es)
CN (1) CN115916756A (es)
AR (1) AR122705A1 (es)
AU (1) AU2021294933A1 (es)
BR (1) BR112022026105A2 (es)
CA (1) CA3187145A1 (es)
CL (1) CL2022003677A1 (es)
CO (1) CO2023000117A2 (es)
CR (1) CR20220644A (es)
IL (1) IL298824A (es)
MX (1) MX2022016455A (es)
PE (1) PE20230838A1 (es)
TW (1) TWI812966B (es)
UA (1) UA130412C2 (es)
WO (1) WO2021259831A1 (es)
ZA (1) ZA202213430B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070118068A (ko) 2004-11-23 2007-12-13 레디 유에스 테라퓨틱스 인코포레이티드 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
US20090227575A1 (en) 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
US20100036123A1 (en) 2008-08-07 2010-02-11 Wyeth Process for the preparation of 2,4-dichloro-7h-pyrrolo[2,3h]quinazoline
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
MX2011009807A (es) 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
PH12012501104A1 (en) 2009-12-04 2014-10-14 Nissan Chemical Ind Ltd 2-pyridone compounds
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
AU2011256455A1 (en) 2010-05-17 2013-01-10 Array Biopharma Inc. Piperidinyl-substituted lactams as GPR119 modulators
WO2012138678A1 (en) 2011-04-04 2012-10-11 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
PH12014500429A1 (en) 2011-08-29 2014-04-14 Ptc Therapeutics Inc Antibacterial compounds and methods for use
WO2013130855A1 (en) * 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MD20150037A2 (ro) 2012-11-08 2015-11-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
US20160096850A9 (en) 2013-08-22 2016-04-07 Genentech, Inc. Alkynyl alcohols and methods of use
RU2719446C2 (ru) * 2014-11-03 2020-04-17 Айомет Фарма Лтд Фармацевтическое соединение
WO2016206101A1 (en) * 2015-06-26 2016-12-29 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
WO2020123395A1 (en) * 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
MX2021007833A (es) * 2018-12-27 2021-10-26 Les Laboratoires Servier Sas Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.

Also Published As

Publication number Publication date
WO2021259831A1 (en) 2021-12-30
CA3187145A1 (en) 2021-12-30
US20230219953A1 (en) 2023-07-13
JP7731381B2 (ja) 2025-08-29
ZA202213430B (en) 2023-08-30
TWI812966B (zh) 2023-08-21
JP2023531020A (ja) 2023-07-20
TW202208361A (zh) 2022-03-01
AR122705A1 (es) 2022-09-28
AU2021294933A1 (en) 2023-02-02
MX2022016455A (es) 2023-02-01
CO2023000117A2 (es) 2023-04-27
CL2022003677A1 (es) 2023-07-28
US12565497B2 (en) 2026-03-03
BR112022026105A2 (pt) 2023-01-17
CN115916756A (zh) 2023-04-04
EP4168392A1 (en) 2023-04-26
KR20230026479A (ko) 2023-02-24
IL298824A (en) 2023-02-01
PE20230838A1 (es) 2023-05-19
UA130412C2 (uk) 2026-02-11

Similar Documents

Publication Publication Date Title
MX2022015886A (es) Derivados de amidopirimidona.
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
RU2403258C2 (ru) Тиазолилдигидроиндазолы
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
MX2024009539A (es) Esteroides neuroactivos y composiciones de estos.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PL402388A1 (pl) Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
TNSN03110A1 (en) Azaindoles.
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
MX2022012898A (es) Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
MX2022016263A (es) Derivados de ciclobutil-urea.
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
JOP20240169A1 (ar) عمليات تحضير عوامل انحلال مستقبلات الإستروجين الانتقائية
SE0101322D0 (sv) Novel compounds
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CR20220644A (es) Derivados de sulfona
MX2021000403A (es) Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.
CR20230331A (es) Derivados de pirazolamida
MX2024003015A (es) Nuevos derivados de quinolina.
AR125059A1 (es) Degradadores selectivos del receptor de estrógeno